Coherus BioSciences Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. My name is Balaji Prasad. I lead the specialty pharmaceuticals coverage for Barclays. And continuing on our spec pharma track for the afternoon, I'm delighted to present the entire management team of Coherus here. So we have Denny Lanfear, CEO; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, CFO; and Theresa LaVallee, Chief Development Officer.
Denny and team, thank you for taking your time to join us this afternoon.
Questions & Answers
So let's dive right into the questions. It's been around a year since you announced your shift to biologics and kind of a strategic shift away from biosimilars, at least no further investment in biosimilars. So as you look at the journey you have passed over the past 1 year, how successful do you think this strategy has been? And what could have been better? Are you happy with your progress as of now?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
